With Isturisa, licensed last year from Novartis, it seems as though the Italian drugmaker has got hold of a therapy that could become lucrative, as well as highly effective for Cushing's disease.
Three months after US approval and a couple of weeks after the European launch, Recordati Industria Chimica & Farmaceutica SPA has announced positive results from a major late-stage study confirming the effectiveness of its Cushing's disease therapy, Isturisa.
The Italian group has reported top-line data from the Phase III LINC-4 study evaluating Isturisa (osilodrostat) in 73 patients with...
Create an account to read this article
Already a subscriber?
The drug that was once commercialized as Relyvrio for ALS failed to show a benefit in adults with progressive supranuclear palsy.
Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.
The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.
The agency is expected to give its final verdict on elamipretide by the end of September.
Recent moves in the industry include an ex-Pfizer exec as the new CEO at Cha Vaccine Institute and a C-suite shuffle at Paragon Therapeutics, plus six other companies get new CFOs.
Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.
The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.
